The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA; (ii) as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays; (iii) the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
AcelRx Pharmaceuticals, Inc. Securities Litigation (2021)
Jun 11, 2021 | AcelRx Pharmaceuticals Inc. Common Stock NASDAQ: ACRX | Case Status: Filed
Filing Deadline: August 09, 2021
If you purchased a significant amount of shares of AcelRx Pharmaceuticals Inc. Common Stock (NASDAQ: ACRX), you have certain options. Investors should contact us before August 09, 2021.
Sign up for free to create a personalized portfolio with tracking and e-mail alerts for AcelRx Pharmaceuticals Inc. Common Stock
First Identified Complaint
Aaron Sneed Jr., et al. v. AcelRx Pharmaceuticals, Inc., et al.
First Identified Complaint Filings
|#||Document Title||Filing Date|
|1||Class Action Complaint for Violations of the Federal Securities Laws||June 8th, 2021|
|2||U.S. District Court Civil Docket||June 9th, 2021|